Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL

Exelixis (EXEL) announced an update on their ongoing clinical study.

The LITESPARK-034 study, also known as MK-6482-034, is a large Phase 3 trial in advanced kidney cancer. It tests whether adding Exelixis’ zanzalintinib to Merck’s belzutifan can help patients live longer and delay disease worsening after prior standard immunotherapy and VEGF-targeted drugs. The outcome may shape future treatment standards in renal cell carcinoma.

The trial compares two tablet regimens taken by mouth. One group receives belzutifan plus zanzalintinib, while the other receives belzutifan plus a matching placebo. Both drugs aim to block signals that drive tumor growth, with the combo designed to deliver a stronger and more durable anti-tumor effect than belzutifan alone.

This is an interventional, randomized study, meaning participants are assigned by chance to one of two treatment arms. It is double blind in practice, so patients, doctors, and key study staff do not know who receives the active combo or placebo, and the main goal is to evaluate treatment benefit in a fair, unbiased way.

The study is currently recruiting and is sponsored by Merck with Exelixis as a collaborator. It was first submitted in March 2026, with the latest update posted in April 2026, signaling active operational progress; primary and final completion dates are not yet posted but will guide when top-line data may reach the market.

For investors, this trial is a key late-stage catalyst for both Merck and Exelixis. Positive data could strengthen belzutifan’s profile and position zanzalintinib as a potential new standard partner in RCC, supporting upside for EXEL and reinforcing Merck’s oncology franchise against players like Bristol Myers and Pfizer, while weak results could pressure sentiment and valuations.

The LITESPARK-034 study remains ongoing and recently updated, and investors can track further protocol and timing details on the ClinicalTrials.gov portal.

To learn more about EXEL’s potential, visit the Exelixis drug pipeline page.